Everest Biotech awards $100,000 antibody grant
Everest Biotech is delighted to announce the winners of its inaugural Antibody Creation Grant. Worth up to $100,000, the funding was offered to research labs around the world. The winners are:
- Professor Gillian Griffith (University of Cambridge, UK): To characterize and investigate the less known components involved in the cytotoxic T cell function.
- Assistant Professor Melinda Larsen (University at Albany-SUNY, USA): To fully investigate and map the presence and localization of proteins involved in the development of salivary glands, leading to a deeper understanding of Sjogren’s syndrome.
- Assistant Professor Bernard Lassegue (Emory University, USA): Looking at the organization and regulation of the components of NADP-oxidases.
- Associate Professor Michael Tuvim (University of Texas, USA): Focusing on the regulation of mucus formation in airways. Everest Biotech and Dr Tuvim will work closely together to generate the required reagents, thus dramatically speeding up the research in this area.
- Professor Michihiro Igarashi (Niigata University, Japan): Investigating the components of growth cones in adult brains. The proteomic approach has identified a number of proteins involved in higher brain functions through these growth cones. Everest Biotech antibodies will be used to further investigate and characterize the mechanisms of neuronal organization and repair, therefore, leading to groundbreaking neuroscience.
Everest Biotech CSO, Dr Jan Voskuil, commented: “The response to the grant was phenomenal, with applicants from all over the world competing for the $100,000. Everest Biotech’s scientific board had a very hard job in picking a single winner, such was the calibre of entries. In the end, we decided to split the prize across five groups that we felt would benefit most from the award, and we congratulate the winners. Everest Biotech is delighted and excited about our contribution to these projects. It is accepted that antigen affinity-purified peptide antibodies complement and often outperform existing monoclonal antibodies. We hope that the variety of winning projects will maximize the impact Everest Biotech will have on the progress in medical science.”
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
